[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carotid-artery-atheroma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carotid-artery-atheroma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100503691","canf-comb-ii-pet-mr-in-atherosclerosis-multisite-100503691",false,"NCT05838547","CANF-Comb-II PET-MR in Atherosclerosis Multisite","PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With Cu[64]-25%-CANF-Comb-II","Inclusion Criteria:\n\n* Adults, 18 years of age or older\n* Asymptomatic carotid artery stenosis patients who have undergone carotid Doppler\u002Fultrasound imaging or other carotid imaging which have demonstrated a ≥ 60% diameter carotid artery stenosis.\n* The treating surgeon has planned either treatment with optimal medical therapy (OMT) alone, or OMT and carotid endarterectomy (CEA) surgical intervention.\n\nExclusion Criteria:\n\n* Inability to receive and sign informed consent.\n* Patients with an unstable clinical condition that in the opinion of the Sponsor-Investigator or designee precludes participation in the study.\n* Inability to tolerate up to 60 minutes in a supine position with arms down at sides for PET-MR imaging.\n* Prior history of CEA or carotid artery stent procedure on the ipsilateral side.\n* Past medical history of TIA or stroke within the last 6 months.\n* Unwilling to comply with study procedures and\u002For unable to be available for the duration of the study outlined in the protocol.\n* Contraindications to MR imaging (pacemaker, brain aneurysm clips, shrapnel, claustrophobia, etc.).\n* Currently pregnant or lactating. All female subjects of childbearing potential must have a documented negative pregnancy test (serum or urine hCG) performed within 24 hours immediately prior to the administration of 64Cu-25%-CANF-Comb or documented post-menopausal defined as the cessation of menses for ≥ 12 months or documentation of having a bilateral oophorectomy and\u002For hysterectomy.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn more about plaque biology in asymptomatic carotid artery stenosis (ACAS) patients through imaging. The main questions it aims to answer are:\n\n* To determine the ability of 64Cu-CANF-Comb positron emission tomography (PET) to risk stratify ACAS patients for stroke event, to include transient ischemic attack or remote ipsilateral intervention.\n* To further understand the role of Natriuretic Peptide Receptor C (NPRC) in the evolution of carotid atherosclerosis.\n\nParticipants will be asked to undergo a carotid PET-magnetic resonance imaging (MRI) examination to assess whether the carotid atherosclerosis uptake of 64Cu-CANF-Comb as measured by PET-MRI correlates with patient outcomes (stroke, transient ischemic attack, or remote ipsilateral intervention).",[24,25,26],"Carotid Atherosclerosis","Asymptomatic Carotid Artery Stenosis","Carotid Artery Atheroma",[28,29,30,31],"Stroke","TIA","Vascular Disease","Cardiovascular Disease","RECRUITING","2026-03-19",{"date":35,"type":36},"2026-03-23","ACTUAL",{"date":38,"type":36},"2023-03-21",{"date":40,"type":20},"2027-05-31",{"name":42,"class":43},"Washington University School of Medicine","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100581282","randomized-controlled-trial-on-carotid-atherosclerosis-screening-in-asymptomatic-smokers-and-hypertensive-adults-prevalence-and-impact-on-cardiovascular-prevention-100581282","NCT06848283","Randomized Controlled Trial on Carotid Atherosclerosis Screening in Asymptomatic Smokers and Hypertensive Adults: Prevalence and Impact on Cardiovascular Prevention","Carotid Atherosclerosis Screening: Epidemiological Profile and Preventive Intervention","CAROTID-CARE","Inclusion Criteria:\n\n* Adults aged ≥40 years and \\\u003C70 years, hypertensive and smokers\n* Registered in ACeS Maia\u002FValongo\n* Willing to participate in the study\n\nExclusion Criteria:\n\n* Inability to provide consent.\n* Patients with a previous stroke, symptomatic coronary artery disease, or symptomatic peripheral artery disease will be excluded.",true,"40 Years","70 Years",{"count":56,"type":20},4780,"INTERVENTIONAL",[59],"NA","Title of the study: Carotid Atherosclerosis Screening: Epidemiological Profile and Preventive Intervention.\n\nObjective: The main objective of this study is to characterize and identify the prevalence of carotid atherosclerosis in adults who are still asymptomatic for vascular disease and to evaluate the impact of detecting carotid atherosclerosis on preventive strategies. The study covers a population of approximately 4,780 patients.\n\nEstimated Duration of the Project: The estimated duration of the project is 36 months, starting in February 2025, with the possibility of an extension if necessary.\n\nEntities that approved the study: This study has been reviewed and approved by the Executive Director and President of the Clinical and Health Council of ACeS Grande Porto III - Maia\u002FValongo, as well as the Health Ethics Committee of the Northern Regional Health Administration (ARS Norte). The Addendum has also been approved by the Ethics Committee of the São João Local Health Unit (ULS São João).\n\nExplanation of the Study:\n\nThis study will take place at ULS São João, including the São João University Hospital Center and the Primary Care Grouping (ACeS) Grande Porto III - Maia\u002FValongo.\n\nThe study includes two groups. Patients in the intervention group will undergo a neck ultrasound (a non-invasive imaging exam) for the early detection of atherosclerotic plaques. Demographic data (sex, age, educational level, employment status), vascular risk factors (smoking, alcohol consumption, blood pressure, and lipid profile), and anthropometric data (waist circumference and BMI) will be documented and analyzed by the research team. Medication, previous treatments, and other preventive initiatives will also be recorded. Glycemic and lipid profiles of participants will be collected.\n\nBased on the results, the individual cardiovascular risk will be calculated using the SCORE2 global cardiovascular risk assessment chart from the European Society of Cardiology, both before and after incorporating ultrasound findings. Subsequently, personalized recommendations for preventive and therapeutic strategies will be developed for each patient and shared with family physicians.\n\nTo identify potential vascular risk biomarkers, venous blood samples will be collected in the intervention group. Patients identified with high-risk atherosclerotic plaques will be referred for further evaluation at the Neurology\u002FCerebrovascular Disease outpatient clinic of the São João University Hospital Center, ULS São João.\n\nPatients in the other group (control group) will follow the same protocol, except for the neck ultrasound. To identify potential vascular risk biomarkers, venous blood collection will be performed in the intervention group during the carotid ultrasound (Doppler ultrasound). Both groups will be reassessed at a later stage. If a participant meets the exclusion criteria for the study, this will be duly explained to them.",[26,62],"Cardiovascular Risk Stratification","NOT_YET_RECRUITING","2025-02-21",{"date":66,"type":36},"2025-02-27",{"date":68,"type":20},"2025-02",{"date":70,"type":20},"2028-02",{"name":72,"class":43},"Universidade do Porto"]